Systematic review and Meta-analysis of efficacy and safety of dienogest in treatment of endometriosis

Table 1 Characteristics of the studies included in the Meta-analysis

Ref.	Study design	Country	Blind	Duration	Intervention	Sample size	Efficacy assessments	Safety assessments
Harada et al[22], 2009	RCT	Japan	Double-blind	24 wk	2 mg/d DNG vs 900 μg/d buserelin	137/134	VAS	BMD change Hot flashes Headache
Strowitzki et al[23], 2010	RCT	Germany Austria Spain Poland Italy Portugal	Open-label	24 wk	2 mg/d DNG vs 3.75 mg/4wk leuprolide	124/128	VAS	Hot flashes Headache
Abdou et al[24], 2018	RCT	Egypt	Open-label	12 wk	2 mg/d DNG vs 3.75 mg/4 wk leuprolide	130/131	VAS	Hot flashes Headache
Lang et al[25], 2018	RCT	China	Double-blind	24 wk	2 mg/d DNG vs placebo	130/132	VAS SAM intake	BMD change E2
Strowitzki et al[26], 2010	RCT	Germany Italy Ukraine	Double-blind	12 wk	2 mg/d DNG vs placebo	102/96	SAM intake	BMD change E2 Headache
Osuga et al[27], 2017	RCT	Japan	Double-blind	16 wk	2 mg/d DNG vs placebo	34/33	VAS SAM intake	E2 Hot flashes
Harada et al[28], 2017	RCT	Japan	DNG: Un-blind Placebo: Blind	24 wk	2 mg/d DNG vs placebo	53/129	VAS

EM: Endometriosis; AD: Adenomyosis; SAM: Supportive analgesic medication; BMD: Bone mineral density; E2: Serum estradiol.